Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
Daniella C. Terenzi(St. Michael's Hospital), David Hess(Western University), Hwee Teoh(St. Michael's Hospital), Ehab Bakbak(The University of Queensland), Aishwarya Krishnaraj(St. Michael's Hospital), Francesco Cosentino(Linköping University), Ronald Goldenberg(LMC Diabetes & Endocrinology (Canada)), Pankaj Puar(St. Michael's Hospital), Subodh Verma(St. Michael's Hospital), Ori D. Rotstein(St. Michael's Hospital)
Cited by 13
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
|European Heart Journal|2013|1.4k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733